Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 1677 results found. Search for [ Sun Pharma ]

Results 1640 to 1660 of 1677
By Dipen Sheth
October 4, 2007
With volatility ebbing from the markets, it is time to stay put with our pickings, but with minor changes.


www.businesstoday.in
September 20, 2007
Enam Securities feels that most pharma companies will continue with lukewarm performance in 2007.


By Dipen Sheth
September 20, 2007
MONEY TODAY portfolios have seen some rejigs. However, more than short-term volatility, it has to do with our long-term objectives.


By Dipen Sheth
September 6, 2007
MONEY TODAY portfolios are for investors in stocks, not traders. And investors can overlook the current volatility, at least for the time being, says Dipen Sheth.


By Narayan Krishnamurthy
August 20, 2007
Sector equity funds allow investors to take a calculated gamble. But while the returns are higher than in a diversified fund, so are the risks.


www.businesstoday.in
July 24, 2007
Here we explain the rationale for choosing each stock in Safe Wealth, the 'safer' of our two portfolios.


www.businesstoday.in
May 3, 2007
The Indian pharma sector is poised to turn a corner on the back of excellent growth in first nine months of 2006-7.


V.K.Sharma
December 28, 2006
Investors keenly watch the monthly updates of mutual funds and jump on any stock that the funds have added to their portfolio.


www.businesstoday.in
May 3, 2007
This selection of research reports gives information and opinions on companies and industries.They are often filled with jargon, which we must reluctantly inflict on readers sincethe excerpts are verbatim. Seven such terms occur in these extracts: EBITDA = EarningsBefore Interest,Tax, Depreciation,Amortisation, EV = Enterprise Value, EPS = Earnings Per Share, PE = Price-Earnings, PAT/PBT = Profit After/ Before Tax,YoY = Year-on-year.


Anamika Butalia
July 7, 2010
Enough of couture and fragrances. The French have far more to offer, and India, for one, can't get enough of their skincare treatments. That's because the products are largely based on hydrotherapy, which is ideal for our skins.


E. Kumar Sharma
June 23, 2010
Ramky has emerged as a leading waste management company. Will a global footprint help it achieve its ambition of being a billion-dollar player?


Suman Layak
June 22, 2010
Businesses — both domestic and global — are forking out big bucks for Indian assets. Could this be the silly season for valuations?


E. Kumar Sharma
June 9, 2010
Piramal's domestic formulations business becomes the latest—and most expensive—acquisition of an Indian drug business by a global pharma major. As the stakes get higher, who's next?


E. Kumar Sharma
November 15, 2009
While MNCs are invading India in a desperate quest for new markets, Indian pharma firms are struggling to expand and rise up the value chain in a tough, competitive environment.


Dipen Sheth
October 28, 2009
Dipen Sheth tries to guess which companies and sectors will make it to the Top 20 slots 10 years from now.


Virendra Verma
September 3, 2009
India’s most valuable pharma firm has stumbled, as a US subsidiary gets on the wrong side of the FDA and a handful of exclusive arrangements come to an end. Can founder Dilip Shanghvi get Sun Pharma back on the road to supernormal profits?


E. Kumar Sharma
August 19, 2009
By refocussing its strategies, Natco Pharma has pulled back from the brink of bankruptcy to power ahead in cancer drugs. Now it is looking for niche areas globally. Can it scale up and take on global competition?


Rachna M. Koppikar
August 19, 2009
As mergers & acquisitions become a way of life at India Inc., CEOs are leaning heavily on their teams of dealmakers who are not too far away from the corner room.


Virendra Verma
March 5, 2009
Sun Pharma rises out of the gloom thanks to its distinctive four-pronged game plan.


Virendra Verma
March 5, 2009
They’ve been posting robust double-digit growth for two quarters now even as their peers struggle to come to terms with the downturn. Virendra Verma finds out what makes these companies tick when business dips?


PAGES 83 OF 84  81828384